On 1st Dec 2016, Beijing Genetech, subsidiary of Uni-Bio Science Group entered into a strategic agreement to co-develop promising oral anti-diabetic drugs (OAD). Acarbose will be the first product developed together, both companies will explore development of another 2 to 3 OAD. Sun-Novo has strong development track record in China with 65 IND approvals, 2 NDA approvals for API, 2 NDA approvals for finished drug.